Navigation Links
Full Agenda Announced for CMAC 2011 - CBI'S 2nd Annual Commercialization and Market Access Congress
Date:10/18/2011

WOBURN, Mass., Oct. 18, 2011 /PRNewswire/ -- CBI is pleased to announce the full agenda for CMAC 2011 - CBI's 2nd Annual Commercialization and Market Access Congress, being held December 6-7, 2011 in Philadelphia, PA. The program, sponsored by Campbell Alliance and McKesson Specialty Care Solutions, delivers pre- and post-launch strategies, dynamic programming and extensive coverage of market access trends.

Anchored by conference chairman, Robert Besthof, Vice President, Commercial Lead, ERP U.S. & Puerto Rico, Pfizer Inc., CMAC 2011 boasts an impressive speaker lineup from AstraZeneca, Baxter, Bristol-Myers Squibb, Daiichi Sankyo, Endo, Eli Lilly, ImClone, InterMune, Metamark Genetics, Grifols, ISTA Pharmaceuticals, Shire, Vertex and many more. Attendees have the opportunity to customize their congress by choosing between workshops, pre- and post-launch tracks and participating in interactive panel discussions. Session highlights include:

  • Product Commercialization Simulation from Candidate Selection through Launch
  • Reimbursement Strategies to Ensure Favorable Coverage, Coding and Payment Decisions
  • The Emergence of Personalized Medicine
  • Global Rollout
  • Brand Commercialization in a Crowded Therapeutic Marketplace
  • Building Specialty Launch Teams
  • Re-Positioning Products Post-Launch
  • KOL Engagement to Optimize Commercialization Efforts

CMAC 2011 is the industry's only opportunity to participate in an executive-level exchange addressing the overarching product development and launch environment, as well as tactical approaches for pricing, reimbursement, product launch, commercial strategy, branding, managed care and HEOR. For more information on the conference or to view the entire agenda, please visit http://www.cbinet.com/cmac2011.  

About CBI:

CBI, a subsidiary of Advans
'/>"/>

SOURCE CBI
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
2. TechConnect World Publishes Conference Agenda Featuring More than 2,700 Presentations Addressing Nano, Bio and Clean Technologies
3. American Society of Anesthesiologists Primary Agenda Displayed Says Dr. Barry Friedberg of Cosmetic Surgery Anesthesia
4. CBI Announces the Agenda for Their West Coast Forum on Clinical Supply Chain Management
5. CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress
6. 'Biopolymers Symposium 2010' Agenda Announced
7. Full Agenda Announced for CBIs Commercialization and Market Access Congress (CMAC 2010)
8. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
9. 2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced
10. First Annual Arizona Biotech Day Announced for October 23rd 2008
11. Presenters Announced For MichBio Expos Emerging Business Showcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development ... for the quarter ended June 30, 2015, corporate ... and management report are available at www.sedar.com ... . "RepliCel expects to launch ...
(Date:8/28/2015)... ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in ... and excellent customer service. Images such as the Fonz in a lab coat and ... flavor to the humdrum spectroscopy field. , FireflySci is proud to be the ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Capital ... solve complex business problems, is pleased to announce their ranking as one of the ... ranking of the fastest-growing private companies across the nation. , “It is truly an ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... a groundbreaking film starring the top equine veterinarians whose ... May 28 Today the Foundation for Biomedical Research ... won a Telly Award in the 30th Annual Telly ... the premier award honoring outstanding local, regional, and cable ...
... Growth Opportunities in Increasing Food Productivity, Decreasing Dependence on ... May 28 DuPont (NYSE: DD ) ... addressing major global market trends, said DuPont CEO Ellen ... Kullman said the company,s research and development efforts are ...
... Inc. today announced that the Company,s product candidate, NT-501, ... Phase 2 clinical trials for retinitis pigmentosa ... the progressive degeneration of rod & cone photoreceptor cells ... peripheral vision and eventually leads to blindness. RP is ...
Cached Biology Technology:The Foundation for Biomedical Research Wins Telly Award for Majestic 2DuPont Innovation Addressing Major Global Market Trends 2DuPont Innovation Addressing Major Global Market Trends 3DuPont Innovation Addressing Major Global Market Trends 4Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 2Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 3Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 4Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 5
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... new sales campaign for Q4 2015. The new marketing ... team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) ... Group is a leader in retail driven marketing and ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... biological terms this question could involve a feedback loop that ... on that information. Although feedback loops are essential and they ... an organ such as the liver to detect if it ... and if it needs to regenerate itself. When such loops ...
... safe procedures for a promising experimental brain-cancer therapy which uses ... For many, this will conjure images of Spiderman's nemesis, ... science fiction, but rather to help to develop a promising ... the yellow Israeli scorpion preferentially attaches to the cells of ...
... Integrated Microbial Genomes (IMG) data management system of the U.S. ... released to the public. IMG 1.5 now contains a total ... and 259 bacterial phages) of which 602 are finished and ... finished and 100 draft genomes sequenced by DOE JGI, bringing ...
Cached Biology News:Study finds how organs monitor themselves during early development 2Study finds how organs monitor themselves during early development 3Study finds how organs monitor themselves during early development 4Radioactive scorpion venom for fighting cancer 2DOE JGI releases IMG 1.5 with curated archaeal genomes 2
... for covering tissue sections and cell preparations immunohistochemically ... insoluble end products. UltraMount Plus can ... or AEC that require an aqueous mounting medium, ... No heating is required prior to use. This ...
... Intracellular (IC) Fixation Buffer, used in ... No. 00-8333), can be used to ... performing intracellular staining of cytokines and ... solutions have been specially formulated for ...
Cytofix Buffer 100 mls...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Biology Products: